$0.46
4.13% yesterday
Nasdaq, Jun 25, 10:00 pm CET
ISIN
IL0011651580
Symbol
PRFX
Sector
Industry

PainReform Ltd Share price

$0.46
-0.24 34.26% 1M
-2.48 84.35% 6M
-2.29 83.27% YTD
-4.62 90.94% 1Y
-29.64 98.47% 3Y
-66.94 99.32% 5Y
-66.94 99.32% 10Y
Nasdaq, Closing price Tue, Jun 25 2024
ISIN
IL0011651580
Symbol
PRFX
Sector
Industry

Key figures

Market capitalization $1.19m
Enterprise Value $-3.07m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.37
P/B ratio (TTM) P/B ratio 0.48
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-12.73m
Free cash flow (TTM) Free cash flow $-8.20m
Cash position $4.33m
EPS (TTM) EPS $-8.21
P/E ratio expected negative
Short interest 1.40%
Show more

Is PainReform Ltd a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.

PainReform Ltd Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast PainReform Ltd:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast PainReform Ltd:

Buy
100%

Financial data from PainReform Ltd

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 0.02 0.02
0% 0%
-
-0.02 -0.02
0% 0%
-
- Selling and administrative expenses 3.38 3.38
23% 23%
-
- Research and development costs 9.32 9.32
79% 79%
-
-13 -13
33% 33%
-
- Depreciation and amortization 0.02 0.02
0% 0%
-
EBIT (operating result) EBIT -13 -13
32% 32%
-
Net profit -13 -13
33% 33%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the PainReform Ltd share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

PainReform Ltd Share News

Neutral
GlobeNewsWire
25 days ago
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bi...
Neutral
GlobeNewsWire
about one month ago
Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy
Neutral
GlobeNewsWire
about 2 months ago
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com.
More PainReform Ltd News

Company profile

PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

Head office Israel
CEO Ilan Hadar
Employees 7
Founded 2007
Website www.painreform.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now